Psychometric validation of the revised SCOPA-Diary Card: expanding the measurement of non-motor symptoms in parkinson's disease

Health and Quality of Life Outcomes

Jane Castelli-Haley¹  Michelle K White²  Philip O Buck¹  Regina Rendas-Baum² 

[1] Teva Neuroscience, Inc., Kansas City, MO, USA;QualityMetric Inc., Lincoln, RI, USA

关键词: non-motor symptoms;    validity;    reliability;    diary;    SCOPA;    quality of life;    Parkinson's disease;   

Others  :  826474
DOI  :  10.1186/1477-7525-9-69

 received in 2011-03-17, accepted in 2011-08-18,  发布年份 2011

【 摘 要 】

Background

To identify key non-motor symptoms of Parkinson's disease (PD) to include in a daily diary assessment for off-time, revise the Scales for Outcomes of Parkinson's disease Diary Card (SCOPA-DC) to include these non-motor symptoms, and investigate the validity, reliability and predictive utility of the Revised SCOPA-DC in a U.S. population.

Methods

A convenience sample was used to recruit four focus groups of PD patients. Based on findings from focus groups, the SCOPA-DC was revised and administered to a sample of 101 PD patients. Confirmatory factor analysis was conducted to test the domain structure of the Revised SCOPA-DC. The reliability, convergent and discriminant validity, and ability to predict off-time of the Revised SCOPA-DC were then assessed.

Results

Based on input from PD patients, the Revised SCOPA-DC included several format changes and the addition of non-motor symptoms. The Revised SCOPA-DC was best represented by a three-factor structure: Mobility, Physical Functioning and Psychological Functioning. Correlations between the Revised SCOPA-DC and other Health-Related Quality of Life scores were supportive of convergent validity. Known-groups validity analyses indicated that scores on the Revised SCOPA-DC were lower among patients who reported experiencing off-time when compared to those without off-time. The three subscales had satisfactory predictive utility, correctly predicting off-time slightly over two-thirds of the time.

Conclusions

These findings provide evidence of content validity of the Revised SCOPA-DC and suggest that a three-factor structure is an appropriate model that provides reliable and valid scores to assess symptom severity among PD patients with symptom fluctuations in the U.S.

【 授权许可】

   
2011 Rendas-Baum et al; licensee BioMed Central Ltd.

【 参考文献 】

• [1]de Lau LM, Breteler MM: Epidemiology of Parkinson's disease. Lancet Neurol 2006, 5(6):525-535.
• [2]Nussbaum RL, Ellis CE: Alzheimer's disease and Parkinson's disease. N Engl J Med 2003, 348(14):1356-1364.
• [3]Adler CH: Nonmotor complications in Parkinson's disease. Mov Disord 2005, 20(Suppl 11):S23-S29.
• [4]Chaudhuri KR, Martinez-Martin P, Schapira AH, Stocchi F, Sethi K, Odin P, Brown RG, Koller W, Barone P, MacPhee G, Kelly L, Rabey M, MacMahon D, Thomas S, Ondo W, Rye D, Forbes A, Tluk S, Dhawan V, Bowron A, Williams AJ, Olanow CW: International multicenter pilot study of the first comprehensive self-completed nonmotor symptoms questionnaire for Parkinson's disease: the NMSQuest study. Mov Disord 2006, 21(7):916-923.
• [5]Cheon SM, Ha MS, Park MJ, Kim JW: Nonmotor symptoms of Parkinson's disease: prevalence and awareness of patients and families. Parkinsonism Relat Disord 2008, 14(4):286-290.
• [6]Martinez-Martin P, Schapira AH, Stocchi F, Sethi K, Odin P, MacPhee G, Brown RG, Naidu Y, Clayton L, Abe K, Tsuboi Y, MacMahon D, Barone P, Rabey M, Bonuccelli U, Forbes A, Breen K, Tluk S, Olanow CW, Thomas S, Rye D, Hand A, Williams AJ, Ondo W, Chaudhuri KR: Prevalence of nonmotor symptoms in Parkinson's disease in an international setting; study using nonmotor symptoms questionnaire in 545 patients. Mov Disord 2007, 22(11):1623-1629.
• [7]Simuni T, Sethi K: Nonmotor manifestations of Parkinson's disease. Ann Neurol 2008, 64(Suppl 2):S65-S80.
• [8]Snyder CH, Adler CH: The patient with Parkinson's disease: part I-treating the motor symptoms; part II-treating the nonmotor symptoms. J Am Acad Nurse Pract 2007, 19(4):179-197.
• [9]Zesiewicz TA, Sullivan KL, Hauser RA: Nonmotor symptoms of Parkinson's disease. Expert Rev Neurother 2006, 6(12):1811-1822.
• [10]Gallagher DA, Schrag A: Impact of newer pharmacological treatments on quality of life in patients with Parkinson's disease. CNS Drugs 2008, 22(7):563-586.
• [11]Racette BA, Hartlein JM, Hershey T, Mink JW, Perlmutter JS, Black KJ: Clinical features and comorbidity of mood fluctuations in Parkinson's disease. J Neuropsychiatry Clin Neurosci 2002, 14(4):438-442.
• [12]Buck PO, Trautman H, Clark J: Scales for assessing nonmotor symptom severity changes in Parkinson's disease patients with symptom fluctuations. International Journal of Neuroscience 2010, 120(8):523-530.
• [13]Quinn NP: Classification of fluctuations in patients with Parkinson's disease. Neurology 1998, 51(2 Suppl 2):S25-S29.
• [14]Hou JG, Lai EC: Overview of Parkinson's disease: clinical features, diagnosis, and management. In Neurorehabilitation in Parkinson's Disease: An Evidence Based Treatment Model. Edited by Trail M, Protas EJ, Lai EC. NJ: Slack Incorporated; 2008:1-40.
• [15]Brooks DJ, Agid Y, Eggert K, Widner H, Ostergaard K, Holopainen A: Treatment of end-of-dose wearing-off in parkinson's disease: stalevo (levodopa/carbidopa/entacapone) and levodopa/DDCI given in combination with Comtess/Comtan (entacapone) provide equivalent improvements in symptom control superior to that of traditional levodopa/DDCI treatment. Eur Neurol 2005, 53(4):197-202.
• [16]Trail M, Protas EJ, Lai EC: Neurorehabilitation in Parkinson's Disease: An Evidence Based Treatment Model. NJ: Slack Incorporated; 2008.
• [17]Stacy M, Hauser R, Oertel W, Schapira A, Sethi K, Stocchi F, Tolosa E: End-of-dose wearing off in Parkinson disease: a 9-question survey assessment. Clin Neuropharmacol 2006, 29(9):312-321.
• [18]Chaudhuri KR, Martinez-Martin P, Brown RG, Sethi K, Stocchi F, Odin P, Ondo W, Abe K, MacPhee G, MacMahon D, Barone P, Rabey M, Forbes A, Breen K, Tluk S, Naidu Y, Olanow W, Williams AJ, Thomas S, Rye D, Tsuboi Y, Hand A, Schapira AH: The metric properties of a novel non-motor symptoms scale for Parkinson's disease: Results from an international pilot study. Mov Disord 2007, 22(13):1901-1911.
• [19]Pursiainen V, Haapaniemi TH, Korpelainen JT, Sotaniemi KA, Myllyla VV: Sweating in Parkinsonian patients with wearing-off. Mov Disord 2007, 22(6):828-832.
• [20]Witjas T, Kaphan E, Regis J, Jouve E, Cherif AA, Peragut JC, Azulay JP: Effects of chronic subthalamic stimulation on nonmotor fluctuations in Parkinson's disease. Mov Disord 2007, 22(12):1729-1734.
• [21]Witjas T, Kaphan E, Azulay JP, Blin O, Ceccaldi M, Pouget J, Poncet M, Cherif AA: Nonmotor fluctuations in Parkinson's disease: frequent and disabling. Neurology 2002, 59(3):408-413.
• [22]Marinus J, Visser M, Stiggelbout AM, Rabey JM, Bonuccelli U, Kraus PH, van Hilten JJ: Activity-based diary for Parkinson's disease. Clin Neuropharmacol 2002, 25(1):43-50.
• [23]Strauss A, Corbin J: Grounded Theory Methodology: an overview. In Strategies of Qualitative Inquiry. Edited by Denzin N, Lincoln Y. London: Sage; 2003:273-285.
• [24]KnowledgePanel® Design Summary. Knowledge Networks [http://www.knowledgenetworks.com/knpanel/KNPanel-Design-Summary.html] webcite 2010.
• [25]Ware JE Jr, Kosinski M, Turner-Bowker DM, Gandek B: How to Score Version 2 of the SF-12® Health Survey (With a Supplement Documenting Version 1). RI: QualityMetric Incorporated; 2002.
• [26]Kosinski M, Bjorner JB: Evaluation of the validity of BDI scores estimated from the SF-36 mental health scale. Quality of Life Research 2009, 1416:A24.
• [27]Jenkinson C, Fitzpatrick R, Peto V, Greenhall R, Hyman N: The PDQ-8: development and validation of a short-form Parkinson's disease questionnaire. Psycho Health 1997, 12:805-814.
• [28]Stacy MA, Murphy JM, Greeley DR, Stewart RM, Murck H, Meng X: The sensitivity and specificity of the 9-item Wearing-off Questionnaire. Parkinsonism Relat Disord 2008, 14(3):205-212.
• [29]Burman PA: A comparative study of ordinary cross validation, k fold cross validation and repeated learning tested methods. Biometrika 1989, 503-514.
• [30]Muthen B: Tobit factor analysis. British Journal of Mathematical and Statistical Psychology 1989, 42:241-250.
• [31]Hu L, Bentler PM: Cutoff criteria for fit indexes in covariance structure analysis: Conventional criteria versus new alternatives. Structural Equation Modeling 1999, 6:1-55.
• [32]Brown T: Confirmatory Factor Analysis for Applied Research. New York: The Guilford Press; 2006.
• [33]Hendrickson AE, White PO: Promax: A quick method for rotation to oblique simple structure. British Journal of Mathematical and Statistical Psychology 1964, 17:65-70.
• [34]Muthen LD, Muthen BO: MPlus User's Guide. 5th edition. CA: Muthen & Muthen; 2007.
• [35]Nunnally JC, Bernstein IH: Psychometric Theory. 3rd edition. New York: McGraw-Hill; 1994.
• [36]Clark LA, Watson D: Constructing validity: Basic issues in objective scale development. Psychological Assessment 1995, 7(3):309-319.
• [37]Kerlinger F: Foundations of Behavioral Research. New York: Holt, Rinehart & Winston; 1973.
• [38]Diggle P, Heagerty P, Liang K: Analysis of Longitudinal Data. second edition. Oxford: University Press; 2002.
• [39]Visser M, van Rooden SM, Verbaan D, Marinus J, Stiggelbout AM, van Hilten JJ: A comprehensive model of health-related quality of life in Parkinson's disease. J Neurol 2008, 255(10):1580-1587.
• [40]Visser M, Verbaan D, van Rooden S, Marinus J, van Hilten J, Stiggelbout A: A Longitudinal evaluation of health-related quality of life of patients with Parkinson's disease. Value Health 2009, 12(2):392-396.
• [41]Forsaa EB, Larsen JP, Wentzel-Larsen T, Herlofson K, Alves G: Predictors and course of health-related quality of life in Parkinson's disease. Mov Disord 2008, 23(10):1420-1427.
• [42]Reuther M, Spottke EA, Klotsche J, Riedel O, Peter H, Berger K, Athen O, Kohne-Volland R, Dodel RC: Assessing health-related quality of life in patients with Parkinson's disease in a prospective longitudinal study. Parkinsonism Relat Disord 2007, 13(2):108-114.
• [43]Jackson DL: Sample Size and number of parameter estimates in Maximum Likelihood Conformatory Factor Analysis: a Monte Carlo investigation. Structural Equation Modeling 2001, 8(2):205-223.
• [44]Park A, Stacy M: Non-motor symptoms in Parkinson's disease. J Neurol 2009, 256(Suppl 3):293-298.
• [45]Lee MA, Walker RW, Hildreth AJ, Prentice WM: Individualized assessment of quality of life in idiopathic Parkinson's disease. Mov Disord 2006, 21(11):1929-1934.
• [46]Goetz CG, Tilley BC, Shaftman SR, Stebbins GT, Fahn S, Martinez-Martin P, Poewe W, Sampaio C, Stern MB, Dodel R, Dubois B, Holloway R, Jankovic J, Kulisevsky J, Lang AE, Lees A, Leurgans S, LeWitt PA, Nyenhuis D, Olanow CW, Rascol O, Schrag A, Teresi JA, van Hilten JJ, LaPelle N: Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): scale presentation and clinimetric testing results. Mov Disord 2008, 23(15):2129-2170.